GoAI
Get started
Lexeo Therapeutics, Inc. Common Stock logo

Lexeo Therapeutics, Inc. Common Stock

LXEO

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.88

−$0.18 · -3.56%

Aug 21, 4:00 PM ET

LXEO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

29

Expensive

Momentum

26

Weakening

Sentiment

43

Mixed

Risk resilience

28

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
R. Nolan Townsend
Listed since
Nov 3, 2023
Employees
59

Market position

Day range

Current $4.88

52-week range

Current $4.88

Open
$5.12
Previous close
$5.06
Volume
509.59K
0.58× average
Average volume
875.79K
Average daily volume
Market cap
383.19M USD
Beta
1.47
Market reference 1
50-day average
$4.708
+3.65% above average
200-day average
$6.5884
-25.93% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
477.58M USD
P/E (TTM)
-4.24×
P/B (TTM)
1.78×
P/S (TTM)
0×
EV / EBITDA
-4.89×
Earnings yield
-18.77%
Free cash flow yield
-18.58%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-40.52%
Return on assets
-37.20%
Return on invested capital
-42.92%

Financial health

Debt / equity
0.03×
Current ratio
11.21×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1035%-2706%-6446%-10187%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Operating margin, FY2021: -3055.94%Operating margin, FY2022: -9252.14%Net margin, FY2021: -3055.04%Net margin, FY2022: -9063.76%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Operating margin FY2021 -3055.94%. Operating margin FY2022 -9252.14%. Net margin FY2021 -3055.04%. Net margin FY2022 -9063.76%.

Income trends

Revenue

654K USD-60.53%

Operating income

−109.26M USD-3.30%

Net income

−99.96M USD-1.66%
Income trends across reported periods12.75M USD−31.62M USD−75.98M USD−120.35M USDRevenue, FY2021: 1.66M USDRevenue, FY2022: 654K USDOperating income, FY2021: −50.64M USDOperating income, FY2022: −60.51M USDOperating income, FY2023: −68.51M USDOperating income, FY2024: −105.77M USDOperating income, FY2025: −109.26M USDNet income, FY2021: −50.62M USDNet income, FY2022: −59.28M USDNet income, FY2023: −66.39M USDNet income, FY2024: −98.33M USDNet income, FY2025: −99.96M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.66M USD. Revenue FY2022 654K USD. Operating income FY2021 −50.64M USD. Operating income FY2022 −60.51M USD. Operating income FY2023 −68.51M USD. Operating income FY2024 −105.77M USD. Operating income FY2025 −109.26M USD. Net income FY2021 −50.62M USD. Net income FY2022 −59.28M USD. Net income FY2023 −66.39M USD. Net income FY2024 −98.33M USD. Net income FY2025 −99.96M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue———654K USD1.66M USD
Gross profit———654K USD1.66M USD
Research and development63.8M USD74.09M USD53.13M USD49.16M USD45.12M USD
Selling, general, and administrative45.46M USD31.68M USD15.38M USD12M USD7.17M USD
Operating expenses109.26M USD105.77M USD68.51M USD61.16M USD52.29M USD
Interest income6.13M USD7.56M USD2.87M USD1.33M USD15K USD
Interest expense206K USD114K USD205K USD91K USD—
Depreciation and amortization2.08M USD2M USD1.84M USD1.15M USD13K USD
Operating income−109.26M USD−105.77M USD−68.51M USD−60.51M USD−50.64M USD
Net income−99.96M USD−98.33M USD−66.39M USD−59.28M USD−50.62M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 4 misses, 1 met estimate
Average EPS surprise
+0.20%
11 comparable reports
Latest EPS result
-0.3
Estimate -0.29 · Miss by 5.20%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.21-0.49-0.77-1.05Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 24, 2025: actual -0.78, estimate -0.87, surprise +10.34%, Beat. Q2 2025, reported May 12, 2025: actual -0.99, estimate -0.8, surprise -23.75%, Miss. Q3 2025, reported Aug 14, 2025: actual -0.6, estimate -0.64, surprise +6.25%, Beat. Q4 2025, reported Nov 5, 2025: actual -0.33, estimate -0.48, surprise +31.25%, Beat. Q1 2026, reported Mar 30, 2026: actual -0.27, estimate -0.32, surprise +15.62%, Beat. Q2 2026, reported May 11, 2026: actual -0.25, estimate -0.29, surprise +13.79%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.3, estimate -0.285, surprise -5.20%, Miss. Q4 2026, reported Dec 14, 2026: actual —, estimate -0.329, surprise —, Comparison unavailable.

LXEO news

globenewswire.com

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled…

Read source
globenewswire.com

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM

Read source
seekingalpha.com

Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript

Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript

Read source
seekingalpha.com

Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline

Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA…

Read source
globenewswire.com

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies

Read source
seekingalpha.com

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript

Read source

LXEO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LXEO

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
12.9M
Weight
0.11%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73—
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
9.64M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24—
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
9.2M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96—
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.34M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81—
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.06M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53—
State Street SPDR S&P Kensho New Economies Composite ETF logoState Street SPDR S&P Kensho New Economies Composite ETFKOMP
Market value
2.84M
Weight
0.10%
AUM
2.71B USD
Expense ratio
0.20%
Price / 1D
$69.24—
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
2.32M
Weight
0.02%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56—
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.64M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25—

Continue in GoAI

Research LXEO

research.disclaimer